MDT Stock Analysis: Medtronic | NYSE
Medical Devices | NYSE, USA | Market Cap: 119.166m USD | 12M Return: 2.6% | IE00BTN1Y115 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 702M
EPS Trend: 87.4%
Qual. Beats: 1
Rev. Trend: 96.4%
Qual. Beats: 5
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Medtronic plc (NYSE: MDT) is a global medical device company founded in 1949 and headquartered in Galway, Ireland. It develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients across the United States, Ireland, and international markets.
The company operates through four main business segments: Cardiovascular Portfolio (offering pacemakers, defibrillators, cardiac ablation products, heart valves, and endovascular stent grafts), Neuroscience Portfolio (including spinal cord stimulation, brain modulation systems, drug infusion systems, and the Accurian nerve ablation system), Medical Surgical Portfolio (covering surgical stapling, robotic-assisted surgery, hernia devices, and patient monitoring products), and a Diabetes Operating Unit (providing insulin pumps, continuous glucose monitoring systems, and the InPen smart insulin pen).
Medtronic competes in the Health Care Equipment sub-industry within the broader Health Care sector, a space dominated by large multinational firms developing capital-intensive, regulated medical technologies. Its diversified portfolio spans chronic disease management, surgical solutions, and neuromodulation, with products sold across multiple medical specialties including cardiology, neurology, orthopedics, and endocrinology.
- MiniMed 780G adoption fuels Diabetes segment growth
- Hugo robot launches compete with Intuitive Surgical
- TAVR market share faces pressure from Edwards Lifesciences
| Net Income: 5.23b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.74 > 1.0 |
| NWC/Revenue: -26.70% < 20% (prev 34.19%; Δ -60.89% < -1%) |
| CFO/TA 0.09 > 3% & CFO 8.04b > Net Income 5.23b |
| Net Debt (26.4b) to EBITDA (9.74b): 2.71 < 3 |
| Current Ratio: 0.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago -0.16% < -2% |
| Gross Margin: 66.69% > 18% (prev 63.44%; Δ 3.25% > 0.5%) |
| Asset Turnover: 40.74% > 50% (prev 37.59%; Δ 3.15% > 0%) |
| Interest Coverage Ratio: 9.36 > 6 (EBIT TTM 6.79b / Interest Expense TTM 725.0m) |
| A: -0.11 (Total Current Assets 1.78b - Total Current Liabilities 11.8b) / Total Assets 93.3b |
| B: 0.36 (Retained Earnings 33.2b / Total Assets 93.3b) |
| C: 0.07 (EBIT TTM 6.79b / Avg Total Assets 92.1b) |
| D: 1.18 (Book Value of Equity 50.2b / Total Liabilities 42.5b) |
| Altman-Z'' = 2.19 = BBB |
| DSRI: 0.10 (Receivables 224.0m/6.26b, Revenue 37.5b/34.2b) |
| GMI: 0.95 (GM 63.44% / 66.69%) |
| AQI: 1.35 (AQ_t 0.90 / AQ_t-1 0.67) |
| SGI: 1.10 (Revenue 37.5b / 34.2b) |
| TATA: -0.03 (NI 5.23b - CFO 8.04b) / TA 93.3b) |
| Beneish M = -3.53 (Cap -4..+1) = AAA |
As of September 10, 2026, the stock is trading at USD 92.39 with a total of 8,094,519 shares traded. Over the past week, the price has changed by +1.92%, over one month by +3.33%, over three months by +15.53% and over the past year by +2.59%.
Current recommended Stop Loss: 87.10 (which is 5.7% or 2.3 ATR below the current price).
Medtronic has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy MDT.
- StrongBuy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 102.9 | 11.4% |
P/E Trailing = 24.695
P/E Forward = 15.4321
P/S = 3.1742
P/B = 2.3818
P/EG = 1.8168
Revenue TTM = 37.5b USD
EBIT TTM = 6.79b USD
EBITDA TTM = 9.74b USD
Long Term Debt = 26.1b USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.54b USD (from shortTermDebt, last quarter)
Debt = 28.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 60.0m
Net Debt = 26.4b USD (calculated: Debt 28.2b - CCE 1.79b)
Enterprise Value = 146b USD (119b + Debt 28.2b - CCE 1.79b)
Interest Coverage Ratio = 9.36 (Ebit TTM 6.79b / Interest Expense TTM 725.0m)
EV/FCF = 23.74x (Enterprise Value 146b / FCF TTM 6.13b)
FCF Yield = 4.21% (FCF TTM 6.13b / Enterprise Value 146b)
FCF Margin = 16.33% (FCF TTM 6.13b / Revenue TTM 37.5b)
Net Margin = 13.93% (Net Income TTM 5.23b / Revenue TTM 37.5b)
Gross Margin = 66.69% ((Revenue TTM 37.5b - Cost of Revenue TTM 12.5b) / Revenue TTM)
Gross Margin QoQ = 64.99% (prev 75.86%)
Tobins Q-Ratio = 1.56 (Enterprise Value 146b / Total Assets 93.3b)
Interest Expense / Debt = 2.57% (Interest Expense 725.0m / Debt 28.2b)
Taxrate = 20.19% (1.33b / 6.60b)
NOPAT = 5.42b (EBIT 6.79b * (1 - 20.19%))
Current Ratio = 0.15 (Total Current Assets 1.78b / Total Current Liabilities 11.8b)
Debt / Equity = 0.56 (Debt 28.2b / totalStockholderEquity, last quarter 50.2b)
Debt / EBITDA = 2.71 (Net Debt 26.4b / EBITDA 9.74b)
Debt / FCF = 4.31 (Net Debt 26.4b / FCF TTM 6.13b)
Total Stockholder Equity = 49.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.68% (Net Income 5.23b / Total Assets 93.3b)
RoE = 10.60% (Net Income TTM 5.23b / Total Stockholder Equity 49.3b)
RoCE = 8.99% (EBIT 6.79b / Capital Employed (Equity 49.3b + L.T.Debt 26.1b))
RoIC = 6.58% (NOPAT 5.42b / Invested Capital 82.2b)
WACC = 5.41% (E(119b)/V(147b) * Re(6.21%) + D(28.2b)/V(147b) * Rd(2.57%) * (1-Tc(0.20)))
Discount Rate = 6.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.02 | Cagr: -1.36%
[DCF] Terminal Value 77.97% ; FCFF base≈5.80b ; Y1≈6.65b ; Y5≈9.79b
[DCF] Fair Price = 94.41 (EV 147b - Net Debt 26.4b = Equity 121b / Shares 1.28b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 87.41 | EPS CAGR: 3.12% | SUE: 4.0 | # QB: 1
Revenue Correlation: 96.38 | Revenue CAGR: 5.63% | SUE: 2.26 | # QB: 5
EPS current Quarter (2026-10-31): EPS=1.33 | Chg30d=-1.21% | Revisions=+0% | Analysts=20
EPS next Quarter (2027-01-31): EPS=1.43 | Chg30d=-0.41% | Revisions=+17% | Analysts=20
EPS current Year (2027-04-30): EPS=5.97 | Chg30d=+0.35% | Revisions=+17% | GrowthEPS=+8.0% | GrowthRev=+7.4%
EPS next Year (2028-04-30): EPS=6.39 | Chg30d=-0.28% | Revisions=+12% | GrowthEPS=+7.1% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: +19% (up=8, down=5)